If data from the interim analysis demonstrates that the initially proposed dose meets the criteria above, enrollment will continue with the same dose administered to 3 additional participants. However, if the interim analysis demonstrates that a new optimized adjusted dose is required, the new adjusted dose will be administered to 3 new participants of the same age range. In subsequent cohorts, the initial dose is also subject to change based upon the results of the interim analysis in previous cohorts.